Exclusive Student Offer

Prime for Young Adults

Get a 6-month trial with premium college perks & fast delivery.

Start Free Trial
Listen Anywhere

Audible Standard Trial

Get 30 days of audiobooks free. Cancel anytime, keep your books.

Claim Free Books

By Mackenzie Tatananni

DOW JONES–Novo Nordisk shares are rising after the British health regulator approved higher doses of the weight-loss drug Wegovy.

The Medicines and Healthcare products Regulatory Agency (MHRA) said on Friday that it had approved a maximum dose of up to 7.2 milligrams (mg) of semaglutide per week – a significant increase from the previous limit of 2.4 mg. The dose is intended to be administered in three separate injections and is strictly intended for adult patients with obesity.

Semaglutide, sold under the brand names Wegovy and Ozempic, has helped Novo Nordisk establish itself in the weight loss market. Ozempic first came to market in 2017 after being approved for the treatment of type 2 diabetes, followed in 2021 by Wegovy for chronic weight management. Despite this pioneering advantage, Eli Lilly’s tirzepatide has gained significant market share, forcing Novo Nordisk to increase its competitiveness.

A step in this direction was the introduction of an oral version (tablet) of the weight loss therapy. The Wegovy pill was introduced in the US on January 5th; A final decision on approval in the UK is expected by the end of the year.

Analysts at Berenberg expect the tablet to bring in around $1 billion this year. Higher-than-expected sales could offset obstacles such as price cuts in the U.S. and expiring patents, analysts said.

The shares of the Danish pharmaceutical company rose by 4.5 percent in Copenhagen. Eli Lilly shares fell by 0.3 percent in premarket trading.

Contact: [email protected]

DJG/DJN/sha/cln

(END) Dow Jones Newswires

January 16, 2026 08:11 ET (13:11 GMT)

By the way: Eli Lilly and other US stocks can even be traded on finanzen.net ZERO until 11 p.m. (without order fees, plus spreads). Open a depot now for free and secure a new customer bonus!

Selected leverage products on Eli Lilly

With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Eli Lilly

Advertising

ttn-28

Get Audible 30-Day Free Trial

As an Amazon Associate, we earn from qualifying purchases.